Q3 FY2026 · ended Sep 30, 2026 · Revenue $13.01B, +14.5% YoY · Filed Nov 4, 2026
Abbott Laboratories (ABT) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $13.0 billion and net income of $920.0 million. Free cash flow was $1.2 billion. As of Sep 30, 2026 it held $5.4 billion in cash and investments and $31.2 billion in total debt.
Revenue
$13.01B
+14.5% vs year-ago quarter
Net income
$920.00M
-44.0% vs year-ago quarter
Operating cash flow
$1.74B
-37.7% vs year-ago quarter
Free cash flow
$1.22B
-46.6% vs year-ago quarter
EPS
$0.53
-43.6% vs year-ago quarter
Dividend per share
$0.63
+6.8% vs year-ago quarter
Shares outstanding
1.73B
-0.4% vs year-ago quarter
Net cash
$-25.76B
Q3 FY2026
Operating margin
13.8%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ABT (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- IL
- Headquarters
- Abbott Park, IL
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1800
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Novo Nordisk A S NVO
- Pfizer Inc PFE
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $13.0B | $12.6B | $11.2B | $11.5B | $11.4B |
| Operating income | $1.4B | $1.7B | $1.3B | $2.3B | $2.1B |
| Net income | $920.0M | $928.0M | $1.1B | $1.8B | $1.6B |
| Diluted EPS | $0.53 | $0.53 | $0.61 | $1.03 | $0.94 |
| Operating cash flow | $1.7B | $2.5B | $1.3B | $3.3B | $2.8B |
| Free cash flow | $1.2B | $2.0B | $916.0M | $2.6B | $2.3B |
| Total assets | $108.2B | $109.2B | $110.4B | $86.7B | $84.2B |
| Stockholders' equity | $51.0B | $51.1B | $52.1B | $52.1B | $51.0B |
| Cash and investments | $5.4B | $6.7B | $8.4B | $9.9B | $8.7B |
| Total debt | $31.2B | $32.6B | $34.0B | $14.1B | $12.9B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Other events
|
Oct 21, 2026 | Oct 21, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 21, 2026 | Oct 21, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Aug 20, 2026 | Aug 20, 2026 |
| 10-Q | Quarterly report | Jul 28, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 16, 2026 | Jul 16, 2026 |
All 1000 Abbott Laboratories SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.